I would act as if this will become public soon, because ethically and practically that is the safest assumption.

The core principle: patient safety first, evidence preserved, regulators informed promptly, and no misleading statements to investors or physicians.
Waiting for “more data” after a credible internal signal of liver failure risk in a mass-market chronic-use drug would create enormous ethical, legal, and enterprise risk.

My decision in one sentence

In the next 48 hours, I would:

1. lock down the facts,
2. escalate to the board,
3. retain outside counsel and independent safety experts,
4. begin immediate expedited regulator engagement rather than waiting 6 months,
5. prepare a public and physician communication plan,
6. consider temporary promotional suspension and urgent label-update actions,
7. ensure the earnings call does not omit a material safety development.

---

Guiding objectives for the first 48 hours

1. Protect patients immediately
2. Preserve credibility with regulators
3. Reduce legal exposure by acting promptly and documenting decisions
4. Avoid securities fraud / misleading disclosure
5. Maintain internal trust and operational control
6. Get ahead of the narrative before leaks occur

---

Assumptions

• The signal is credible enough that the internal research team has elevated it.
• This is a serious adverse event: liver failure.
• The incidence is rare but material given 4 million patients and chronic use.
• Approximate cumulative risk over 5 years: 1 in 8,000. Across 4 million patients, that is potentially hundreds of cases over time.
• Current labeling does not warn of this risk.
• Legal says “formal regulatory reporting” would take 6 months; I would not accept that as a reason for delay. There are often ways to make prompt preliminary safety notifications or seek urgent regulator guidance before a full formal package is complete.

---

Hour-by-hour action plan: first 48 hours

Hour 0–1: Activate crisis command

Actions

• Convene an immediate confidential emergency meeting with:
  • Chief Medical Officer
  • Head of Pharmacovigilance / Drug Safety
  • General Counsel
  • Chief Regulatory Officer
  • Chief Compliance Officer
  • CFO
  • Head of Investor Relations
  • Head of Corporate Communications
  • Head of Manufacturing / Supply Chain
  • HR leader
• Establish a “war room” and 6-hour reporting cadence.
• Issue a legal hold on all documents, emails, analyses, and drafts related to the drug and signal.

Why

• This is a patient safety, legal, and disclosure event.
• The legal hold protects against spoliation claims and forces disciplined documentation.
• Centralizing decision-making prevents conflicting actions and leaks.

---

Hour 1–3: Verify the signal and define decision thresholds

Actions

• Require the internal research team to present:
  • Source of the signal
  • Statistical strength
  • Data set used
  • Confounders
  • Severity and reversibility
  • Time-to-event
  • Dose relationship
  • Known risk factors
  • Whether specific populations are at higher risk
• Ask pharmacovigilance to pull:
  • Existing spontaneous adverse event reports
  • Any liver enzyme trends from trials or post-market studies
  • Foreign regulatory correspondence
  • Medical information inquiries that may have hinted at liver toxicity
• Ask for three evidence buckets by the end of Hour 6:
  1. What we know
  2. What we suspect
  3. What we do not know

Why

• I do not need perfect certainty to act, but I need enough confidence to justify immediate mitigation.
• The distinction between “signal” and “established causality” matters for wording, but not acting until causality is perfect is dangerous.

---

Hour 3–4: Engage outside experts

Actions

• Retain:
  • External FDA/regulatory counsel
  • Securities counsel
  • Independent hepatology expert
  • Independent pharmacoepidemiology expert
  • Crisis communications firm with healthcare/regulatory experience
• Ask external counsel to advise on:
  • Immediate reporting pathways
  • Duties to regulators in each major market
  • Materiality for securities disclosure
  • Board fiduciary obligations
• Ask independent medical experts for a same-day preliminary review.

Why

• Independent experts improve decision quality and credibility.
• Outside counsel helps preserve privilege and reduce the risk that internal legal thinking becomes too defensive or too slow.
• If later scrutinized, prompt use of independent experts shows good-faith governance.

---

Hour 4–6: Immediate commercial risk controls

Actions

• Freeze all new promotional campaigns, speaker programs, and aggressive sales pushes for the drug.
• Instruct the sales force:
  • No new efficacy-comparison claims
  • No minimization of safety discussions
  • Route all clinician questions to medical affairs
• Pause direct-to-consumer ad placements if possible, pending review.
• Tell manufacturing and supply chain to prepare contingency scenarios:
  • continued supply
  • restricted distribution
  • possible recall if regulators request it
• Start a draft Dear Healthcare Provider letter and FAQ.

Why

• Continuing normal promotion after learning of a serious unlabelled risk is ethically indefensible and legally hazardous.
• We should not abruptly stop supply without clinical and regulatory assessment because many chronic pain patients may depend on the drug and alternatives may be worse for some.
• But we should stop behavior that looks like “selling through the problem.”

---

Hour 6–8: Preliminary legal and ethical decision point

Actions

• Review the initial evidence package.
• If the signal is credible, make these internal decisions:
  1. We will not wait 6 months to notify regulators.
  2. We will prepare for prompt preliminary disclosure to health authorities.
  3. We will not make any public statement that omits a known material safety issue.
  4. We will recommend urgent label review and risk communication.
• Instruct regulatory affairs to draft a preliminary notification to the FDA and other key agencies requesting urgent discussion within 24 hours.
• Instruct medical affairs to draft interim physician guidance:
  • monitor liver function
  • identify symptoms warranting discontinuation
  • caution in high-risk populations
  • do not stop therapy without physician supervision unless acute symptoms occur

Why

• At this point the company’s posture is set. Delay becomes the core source of liability.
• A preliminary regulator notification is not the same as a full adjudicated filing, but it establishes transparency and good faith.
• Interim clinician guidance reduces patient harm before a formal label update is complete.

---

Hour 8–10: Prepare board materials

Actions

• Build a board deck with:
  • facts and uncertainty
  • patient exposure estimate
  • worst-case and best-case scenarios
  • legal and regulatory obligations
  • options analysis:
    • wait
    • silent investigation
    • immediate regulator engagement + risk communication
    • voluntary temporary market action
  • recommended path
• Include explicit risk analysis of waiting:
  • patient harm
  • punitive regulator response
  • securities litigation
  • product liability
  • whistleblower/leak risk
  • criminal exposure if concealment is inferred
  • reputational destruction far beyond a 40% stock drop
• Ask outside counsel and independent safety expert to attend the board meeting.

Why

• Board members need to understand that “wait for more data” may feel financially prudent but is likely the most expensive option if the issue emerges externally.
• Good governance requires a documented, informed board process.

---

Hour 10–12: Internal communications to top leadership

Actions

• Brief the executive leadership team under confidentiality.
• Tell them:
  • patient safety comes first
  • promotion is paused
  • all inquiries go through a central response team
  • no deletion of records
  • leaks are harmful but retaliation against safety escalations will not be tolerated
• Ask HR and compliance to open an employee hotline category for concerns related to the drug.

Why

• Employee morale and trust depend on seeing ethical leadership immediately.
• If employees believe leadership is hiding a risk, leaks become almost certain.
• Whistleblower protection is both ethical and practical.

---

Hour 12–16: Regulator outreach prep and disclosure analysis

Actions

• Regulatory affairs and external regulatory counsel finalize:
  • preliminary signal summary
  • proposed near-term actions
  • request for urgent agency meeting / call
• Securities counsel and CFO analyze:
  • whether this is material nonpublic information
  • what must be said on the upcoming earnings call
  • whether to issue an 8-K or equivalent disclosure
  • whether insider trading blackout must be imposed immediately
• Impose immediate insider trading blackout for directors, officers, and relevant employees.
• Suspend any planned share buyback decisions until disclosure analysis is complete.

Why

• This is very likely material due to the drug’s size, seriousness of the risk, and likely impact on revenue and stock price.
• Insider trading controls are mandatory from both legal and moral standpoints.
• Any repurchases while aware of this issue would be disastrous.

---

Hour 16–20: Build patient safety response infrastructure

Actions

• Stand up a medical information and patient support command center:
  • train call center staff
  • create escalation pathways for suspected liver symptoms
  • coordinate with pharmacovigilance for rapid adverse event capture
• Draft patient-facing materials in plain language:
  • what symptoms may suggest liver injury
  • when to seek urgent care
  • don’t stop medication abruptly without consulting a doctor unless urgent symptoms arise
• Prepare a liver monitoring recommendation framework for clinicians.

Why

• If disclosure occurs, inbound calls from patients and clinicians will spike immediately.
• A poor response center can create additional harm and PR damage.
• Enhanced adverse-event capture also improves the evidence base quickly.

---

Hour 20–24: First direct regulator contact

Actions

• Contact FDA and other major regulators directly through appropriate urgent safety channels.
• Communicate:
  • a new serious safety signal has been identified
  • current label does not adequately reflect the risk
  • preliminary estimate and limitations
  • we are preparing complete data
  • we have paused promotion and are preparing interim risk communications
  • we request urgent guidance on label changes / Dear HCP communication / monitoring recommendations
• Document every communication meticulously.

Why

• Regulators hate surprises more than bad news.
• Early transparent contact materially improves long-term regulatory trust.
• It also reduces the chance regulators accuse the company of concealment.

---

Day 2

Hour 24–28: Board meeting

Actions

• Hold the board meeting earlier than scheduled if possible.
• Present recommendation:
  1. immediate regulator engagement
  2. immediate suspension of promotional activity
  3. preparation for public disclosure in connection with earnings if required
  4. urgent physician communication once aligned with regulators
  5. no insider trading; blackout effective immediately
  6. formation of a special board safety oversight committee
• Ask the board to approve:
  • external independent review
  • litigation reserve planning
  • patient assistance funding if treatment transition becomes necessary
  • compensation and clawback review if prior incentives created pressure to suppress safety signals
• Record dissent clearly if some directors still prefer delay.

Why

• The board must be brought into a documented, informed decision.
• If some directors argue for waiting, the minutes should reflect that management recommended prompt action based on safety and legal obligations.
• A safety oversight committee demonstrates seriousness.

---

Hour 28–32: Earnings call and public disclosure prep

Actions

• Rewrite earnings script, Q&A, and forward guidance assumptions.
• Remove any statement that could be misleading in light of the new risk.
• Prepare likely disclosures along these lines:
  • we have identified a serious safety signal involving rare liver failure
  • we are urgently evaluating it
  • we have notified/are notifying regulators
  • we are taking precautionary measures including promotional pause and physician outreach
  • financial impact is under assessment
• Decide whether to pre-announce before earnings rather than wait for the call, based on securities counsel advice.

Why

• If management speaks on earnings without disclosing a known material threat, that creates massive securities liability.
• It is better to take one clean hit than compound it by appearing deceptive.

---

Hour 32–36: PR and stakeholder strategy

Actions

• Finalize messaging for:
  • patients
  • prescribers
  • regulators
  • employees
  • investors
  • media
• Core message:
  • patient safety is our priority
  • as soon as the signal was identified and assessed as credible, we acted
  • we are working with regulators transparently
  • patients should consult their physicians; do not panic or abruptly stop without guidance
• Identify spokespersons:
  • CMO for medical questions
  • CEO for accountability and values
  • IR for financial questions
• Prepare for hostile questions:
  • “How did you miss this?”
  • “Did you know earlier?”
  • “How many deaths?”
  • “Why didn’t you pull the drug?”
  • “Were executives selling stock?”

Why

• In crises, inconsistency kills credibility.
• The tone must be accountable, not defensive.
• We must avoid overpromising or sounding certain where facts are still evolving.

---

Hour 36–40: Employee all-hands planning

Actions

• Draft an internal CEO note and prepare manager talking points.
• Tell employees:
  • what is known
  • what is not known
  • what actions are being taken
  • the importance of directing all external inquiries properly
  • our values require prompt action
• Provide support resources for customer-facing teams who will bear the brunt of physician and patient anger.

Why

• Employees are ambassadors and also potential sources of rumor.
• Honest internal communication protects morale and reduces fear.
• If employees learn the truth from media first, trust collapses.

---

Hour 40–44: Operationalize risk mitigation

Actions

• Medical and regulatory teams finalize:
  • draft label amendment proposals
  • clinician monitoring recommendations
  • contraindication or high-risk subgroup restrictions if warranted by the data
• Commercial team finalizes shutdown of active promotional tactics.
• Pharmacovigilance initiates intensified surveillance with daily review.
• Finance begins scenario modeling:
  • 40% stock drop
  • reduced prescribing
  • litigation reserves
  • covenant impacts
  • capital allocation freeze options

Why

• We need substance behind our words.
• Intensified monitoring can both protect patients and produce better data quickly.
• Financial preparedness helps prevent panic responses after disclosure.

---

Hour 44–48: Final decision checkpoint and launch readiness

Actions

• Hold a final executive checkpoint:
  • confirm regulator contacts made
  • confirm board approval / record of decisions
  • confirm blackout and disclosure controls
  • confirm earnings call script
  • confirm physician, patient, and employee materials
• If regulator feedback supports immediate communication, prepare to issue:
  • press release / securities filing if required
  • physician letter
  • patient FAQ
  • employee memo
• If exact public timing remains under legal review, ensure the earnings call cannot proceed with incomplete or misleading statements.
• Schedule daily safety review meetings for the next two weeks.

Why

• By Hour 48, the company must be ready to communicate and execute.
• The biggest failure mode in crises is discovering the issue but entering public events unprepared or saying something misleading.

---

What I would specifically advocate at the board meeting

My recommendation

Do not wait for more data before acting.
Act now on a precautionary basis.

Specifically:

• Immediate preliminary regulator notification
• Immediate promotional pause
• Immediate insider trading blackout
• Prepare urgent physician risk communication
• Update earnings disclosure
• Launch independent review

Why not “wait”?

Because waiting creates the worst combination of outcomes:

• more preventable patient injuries
• more severe legal exposure
• worse regulatory consequences
• larger reputational damage when delay is discovered
• stronger evidence of conscious disregard by management and board
• likely bigger long-term stock collapse than 40%

A 40% stock drop is painful. A concealment narrative can destroy the company.

---

Key legal reasoning

I am not giving legal advice, but from a CEO perspective the legal posture should be:

1. Product liability risk

   • Once aware of a serious unlabelled risk, failure to warn becomes much harder to defend.

2. Regulatory risk

   • Regulators may tolerate uncertainty; they do not tolerate concealment.
   • Early engagement can reduce sanctions and preserve credibility.

3. Securities law risk

   • This appears likely to be material nonpublic information.
   • Upcoming earnings call makes omission especially dangerous.

4. Board fiduciary duty

   • Directors have oversight obligations for mission-critical compliance and safety risk.
   • A documented “wait despite known patient safety signal” decision could be devastating in litigation.

5. Document preservation

   • Essential immediately.

---

Ethical reasoning

Ethically, the question is straightforward:

• The drug helps many patients.
• The risk is rare, but serious and previously undisclosed.
• Patients and physicians can only make informed decisions if they know the risk.
• We do not need perfect certainty before warning people about a credible risk of liver failure.

Ethics also align with long-term shareholder value here. Companies usually suffer more from cover-up than from bad news.

---

Financial implications and how I’d frame them

Yes, disclosure may cause:

• stock decline
• lower prescriptions
• litigation
• analyst downgrades
• pipeline trust discount

But prompt action also protects value by:

• preserving regulator relationships
• reducing punitive enforcement risk
• limiting future injuries and damages
• strengthening defense that management acted responsibly once informed
• preserving employee commitment
• avoiding scandal amplification

I would tell the board and investors:

“We are taking a near-term financial hit to protect patients and preserve the company’s integrity and long-term license to operate.”

---

PR strategy in one line

Be early, factual, accountable, and medically useful.

Not:

• defensive
• vague
• self-congratulatory
• prematurely certain
• overly lawyered

Good message:

“A serious new safety signal was identified. We acted immediately, notified regulators, paused promotion, and are working urgently to provide physicians and patients with updated guidance.”

---

Employee morale

Employees will watch for one thing: do leaders choose patients or the quarter?

If leadership chooses patients:

• morale may be shaken but pride can remain
• retention of top scientific talent is more likely
• internal whistleblowing risk drops

If leadership chooses delay:

• internal trust fractures
• leaks become likely
• long-term culture damage is severe

---

Bottom line

In the next 48 hours, I would treat this as a full enterprise safety crisis and move immediately toward regulator engagement and controlled disclosure.

The single most important decision:

I would refuse to wait for “more data” before taking precautionary action.

Because once we know there may be a rare but serious risk of liver failure in millions of chronic-use patients, the cost of delay is measured not just in dollars, but in preventable harm—and eventually in the company’s credibility, legal survival, and moral legitimacy.

If you want, I can also turn this into:

1. a one-page board memo,
2. a crisis command structure chart, or
3. a draft earnings-call statement.